CCM
RPRX icon

Coldstream Capital Management’s Royalty Pharma RPRX Stock Holding History

Coldstream Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,475
Closed -$45.9K – 2877
2025
Q1 		$45.9K Buy
+1,475
New +$46.8K ﹤0.01% 1752

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Coldstream Capital Management's RPRX Position: Q2 2025 in Review

Coldstream Capital Management sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 1,475 shares — an estimated $45.9K sold.

Coldstream Capital Management first reported a position in RPRX in Q1 2025 and held it in 1 quarter. The position peaked at $45.9K in Q1 2025. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Coldstream Capital Management reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 1,475 Royalty Pharma shares in Q2 2025, an estimated $45.9K.
  • Coldstream Capital Management first reported a position in Royalty Pharma in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Royalty Pharma position peaked at $45.9K in Q1 2025.
  • 455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.